⌘K
t
Nuformix plc announced on March 19, 2024, that all eleven resolutions proposed to shareholders at its Annual General Meeting were duly passed by way of a poll vote. The "For" votes for these resolutions ranged from 92.73% to 97.90% of the total votes cast for each, from the company's issued share capital of 819,309,368 ordinary shares.
| Date | 19 Mar 2024 |
| Time | 14:39:02 |
| Category | AGMs and other meetings |
| ID | 4695H |
Nuformix plc
("Nuformix" or the "Company")
Result of Annual General Meeting
Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces that the Annual General Meeting ("AGM") of Nuformix plc was held earlier today and all resolutions put to shareholders were duly passed and approved by way of a poll vote. The results of the poll, including proxies received ahead of the AGM, are reported below:
|
|
Resolution |
Ordinary/ Special |
For |
|
Against |
|
Total votes cast |
|
|
|
|
No. of votes |
% |
No. of votes |
% |
|
|
1 |
To receive the annual report and accounts for the year ended 30 September 2023
|
Ordinary |
142,381,407 |
97.38% |
3,824,784 |
2.62% |
146,206,191 |
|
2 |
To approve the annual report on remuneration
|
Ordinary |
142,812,526 |
97.60% |
3,505,839 |
2.40% |
146,318,365 |
|
3 |
To re-appoint Daniel Gooding as a director
|
Ordinary |
141,901,631 |
97.81% |
3,179,490 |
2.19% |
145,081,121 |
|
4 |
To re-appoint Julian Gilbert as a director
|
Ordinary |
141,901,631 |
97.81% |
3,179,490 |
2.19% |
145,081,121 |
|
5 |
To re-appoint Madeleine Kennedy as a director
|
Ordinary |
141,881,631 |
97.75% |
3,270,050 |
2.25% |
145,151,681 |
|
6 |
To re-appoint Kreston Reeves LLP as auditor
|
Ordinary |
142,139,182 |
97.90% |
3,055,316 |
2.10% |
145,194,498 |
|
7 |
To authorise the directors to determinethe auditor's fees
|
Ordinary |
141,874,740 |
97.71% |
3,319,758 |
2.29% |
145,194,498 |
|
8 |
To authorise the directors to allot shares
|
Ordinary |
136,385,306 |
93.95% |
8,785,230 |
6.05% |
145,170,536 |
|
9 |
To authorise the directors to disapply pre-emption rights
|
Special |
134,565,189 |
92.73% |
10,553,347 |
7.27% |
145,118,536 |
|
10 |
To authorise the Company to purchase its own shares
|
Special |
135,812,749 |
94.11% |
8,504,877 |
5.89% |
144,317,626 |
|
11 |
To authorise calling of a general meeting on 14 clear days' notice
|
Special |
142,106,241 |
97.84% |
3,141,610 |
2.16% |
145,247,851 |
A vote withheld is not a vote in law and is not counted in the calculation of votes validly cast for or against a resolution.
The Company's issued share capital is 819,309,368 ordinary shares of £0.001 each.
Enquiries:
|
Nuformix plc |
|
|
Dr Dan Gooding, Executive Director
|
Via IFC Advisory
|
|
Stanford Capital Partners Limited |
|
|
Tom Price / Patrick Claridge (Corporate Finance) |
+44 (0) 20 3650 3650 |
|
Bob Pountney (Corporate Broking) |
+44 (0) 20 3650 3652
|
|
IFC Advisory Limited |
|
|
Tim Metcalfe Zach Cohen |
+44 (0) 20 3934 6630 |
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has an early-stage pipeline of preclinical and Phase 1-ready assets with potential for significant value and early licensing opportunities.
For more information, please visit www.nuformix.com.